Aging vessels – specific atherosclerosis and its clinical outcome – are the major cause of death and morbidity in developed countries. Age and abnormalities in plasma lipoprotein concentrations belong to the most predictive risk factors for atherosclerosis, myocardial infarction and stroke.

The aim of our studies is the identification of interrelationships between the aging process and the lipoprotein metabolism and the development of anti-atherogenic and anti-aging therapeutic strategies. For this purpose we use molecular biology, protein chemistry and cell biology methods. Various disease and animal models may help to explain fundamental aspects of aging and concomitant changes in lipid metabolism. These include fibroblasts from patients with Hutchinson-Gilford Progeria and fam-lial HDL deficiency (Tangier Disease).